|Awarded On||August 16, 2017|
|Title||Novel Regulation and Function of TAK1 in Mutant Kras-driven Development of Pancreatic Ductal Adenocarcinoma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Paul Chiao|
Pancreatic cancer (PDAC) is the fourth leading cause of cancer mortality with 46,420 new cases in 2014 in the USA and is projected to surpass breast, prostate, and colorectal cancers as the second leading cause of cancer-related deaths by 2030 (Rahib et al., Cancer Res, 2014). At diagnosis, approximately 80% of PDAC patients have locally an advanced or metastatic disease and a median survival duration of less than 6 months. The 5-year survival rate has remained at 1%-3% for the past 30 years. Therefore, determining an effective drug target for PDAC is one of the greatest challenges in cancer research. Mutant Kras is detected in almost 90% of PDAC cases and is required not only for the initia...